Ustojchivaja effektivnost' alemtuzumaba u patsientov s vysokoaktivnym remittirujuschim rassejannym sklerozom, kotorye imeli neoptimal'nyj otvet na predshestvujuschuju terapiju: dannye 3-letnego nabljudenija v ramkah issledovanija CARE-MS II (Durable Efficacy of Alemtuzumab In Patients with highly active Relapsing-Remitting Multiple Sclerosis who had An Inadequate Response to Prior Therapy: CARE-MS II 3-year data)

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Singer B.

Krieger S.

Amezcua L.

Margolin D.H.

Kasten L.

Hartung H.-P.

Ustojchivaja effektivnost' alemtuzumaba u patsientov s vysokoaktivnym remittirujuschim rassejannym sklerozom, kotorye imeli neoptimal'nyj otvet na predshestvujuschuju terapiju: dannye 3-letnego nabljudenija v ramkah issledovanija CARE-MS II (Durable Efficacy of Alemtuzumab In Patients with highly active Relapsing-Remitting Multiple Sclerosis who had An Inadequate Response to Prior Therapy: CARE-MS II 3-year data)

Authors:

Boĭko A.N., Singer B., Krieger S., Amezcua L., Margolin D.H., Kasten L., Hartung H.-P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8‑2): 53‑54

Downloaded: 3

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Boĭko AN, Singer B, Krieger S, Amezcua L, Margolin DH, Kasten L, Hartung H-P. Ustojchivaja effektivnost' alemtuzumaba u patsientov s vysokoaktivnym remittirujuschim rassejannym sklerozom, kotorye imeli neoptimal'nyj otvet na predshestvujuschuju terapiju: dannye 3-letnego nabljudenija v ramkah issledovanija CARE-MS II (Durable Efficacy of Alemtuzumab In Patients with highly active Relapsing-Remitting Multiple Sclerosis who had An Inadequate Response to Prior Therapy: CARE-MS II 3-year data). S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8‑2):53‑54. (In Russ.)